BMJ3d
Settings and artefacts relevant in colour/power Doppler ultrasound in rheumatology
The Parker Institute, Frederiksberg Hospital, Copenhagen University Hospital, The Capital Region of Denmark, DK-2000 Copenhagen F, Denmark Søren Torp-Pedersen, The Parker Institute, Frederiksberg ...
BMJ6d
Global, regional and national burden of osteoarthritis 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017
Objectives To report the level and trends of prevalence, incidence and years lived with disability (YLDs) for osteoarthritis (OA) in 195 countries and territories from 1990 to 2017 by age, sex and ...
BMJ12d
Single-cell RNA-seq analysis identifies meniscus progenitors and reveals the progression of meniscus degeneration
Correspondence to Dr Zhiqi Zhang, Department of Joint Surgery, Sun Yat-sen University First Affiliated Hospital, Guangzhou 510080, China; zhzhiqi{at}mail.sysu.edu.cn; Dr Weiming Liao; ...
BMJ9d
Acod1-mediated inhibition of aerobic glycolysis suppresses osteoclast differentiation and attenuates bone erosion in arthritis
Objectives Metabolic changes are crucially involved in osteoclast development and may contribute to bone degradation in rheumatoid arthritis (RA). The enzyme aconitate decarboxylase 1 (Acod1) is known ...
BMJ2d
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or ...
BMJ11d
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Correspondence to Dr Antonis Fanouriakis, Rheumatology and Clinical Immunology Unit, “Attikon” University Hospital, Athens 12462, Greece; afanour{at}med.uoa.gr Our objective was to update the EULAR ...
BMJ3d
Immune cell multiomics analysis reveals contribution of oxidative phosphorylation to B-cell functions and organ damage of lupus
Correspondence to Dr Keishi Fujio, Department of Allergy and Rheumatology, The University of Tokyo, Bunkyo-ku, Tokyo, Japan; fujiok-int{at}h.u-tokyo.ac.jp; Dr Yukiko Iwasaki, Department of Palliative ...
BMJ7d
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
3 Center for Applied Statistics and School of Statistics, Renmin University of China, Beijing, China Objectives Open-labelled clinical trials suggested that low-dose IL-2 might be effective in ...
BMJ12d
Long-term structural and symptomatic effects of intra-articular sprifermin in patients with knee osteoarthritis: 5-year results from the FORWARD study
2 Ludwig Boltzmann Institute for Arthritis and Rehabilitation, Paracelsus Medical University, Salzburg, Austria Objective The FORWARD (FGF-18 Osteoarthritis Randomized Trial with Administration of ...
BMJ6d
Horizontal fissuring at the osteochondral interface: a novel and unique pathological feature in patients with obesity-related osteoarthritis
Correspondence to Professor Minghao Zheng, Centre for Orthopaedic Reseach, University of Western Australia, Perth WA 6009, Australia; minghao.zheng{at}uwa.edu.au; Associate Professor Christopher Jones ...
BMJ3mon
Imaging mass cytometry-based characterisation of fibroblast subsets and their cellular niches in systemic sclerosis
Objectives Transcriptomic data demonstrated that fibroblasts are heterogeneous with functionally diverse subpopulations. Although fibroblasts are key effector cells of fibrotic diseases such as ...
BMJ5mon
Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis
Objectives Rheumatoid arthritis (RA) is an autoimmune disease characterised by aggressive fibroblast-like synoviocytes (FLSs). Very few RA patients-derived FLSs (RA-FLSs)-specific surface signatures ...